Detail akcie Medincell Reg S online

Business Summary: Medincell SA is a France-based manufacturer of biological products and pharmaceutical preparations. The Company is focused on the development of therapeutic solutions with worldwide access. The Company works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
Financial Summary: BRIEF: For the six months ended 30 September 2025, Medincell SA revenues increased 35% to EUR11.6M. Net loss increased 10% to EUR16.1M. Revenues reflect Revenue Received as Development Benefits increase of 34% to EUR7.4M, Licences, Milestones, Royalties increase of 53% to EUR4.2M. Higher net loss reflects Research & Development Expense - Balanci increase from EUR3.2M to EUR6.5M (expense).